This "Seborrhoeic Dermatitis - Pipeline Insight, 2021," report provides comprehensive insights on 5+ companies and 5+ pipeline drugs in the Seborrhoeic Dermatitis pipeline landscape. It covers the drug profiles in the pipeline, including clinical and non-clinical phase products. It also covers the therapeutic assessment by product type, stage, route of administration and molecule type. It further highlights the inactive pipeline products in this space.
Geography covered
- Global coverage
Seborrhoeic Dermatitis Understanding
Seborrhoeic Dermatitis: Overview
Seborrheic dermatitis is a chronic inflammatory dermatological condition that usually affects areas of the body with a high density of sebaceous glands, such as the scalp, face, chest, back, axilla and groin. Overall, it has been reported to affect about 4% of the population. The cause of seborrheic dermatitis is not fully understood, but it is thought to be triggered by overgrowth of a harmless yeast called Malassezia that lives on the skin, or an overreaction of the skin's immune system to this yeast. The diagnosis is based on the location and appearance of the rash or lesion. Skin biopsy may be helpful but is rarely indicated. Seborrhoeic dermatitis is managed with treatment that reduces the level of skin yeast - these include creams and shampoos that can be used safely long term.
The “Seborrhoeic Dermatitis- Pipeline Insight, 2021” report provides comprehensive insights into the current scenario and growth prospects across the indication. A detailed picture of the Seborrhoeic Dermatitis pipeline landscape is provided, which includes the disease overview and Seborrhoeic Dermatitis treatment guidelines. The assessment part of the report includes an in-depth Seborrhoeic Dermatitis commercial assessment and clinical assessment of the pipeline products under development. The report provides a detailed description of the drug, which includes the drug's mechanism of action, clinical studies, NDA approvals (if any), and product development activities that include the technology, Seborrhoeic Dermatitis collaborations, licensing, mergers and acquisitions, financing, designations, and other product-related details.
Highlights of the report
- The companies and academics are working to assess challenges and look for opportunities that can influence research and development of seborrhoeic dermatitis. The treatments under development are focused on new approaches to the treatment/improvement of Seborrhoeic Dermatitis.
Seborrhoeic Dermatitis Emerging Drugs Chapters
This segment of the Seborrhoeic Dermatitis report encapsulates its detailed analysis of various drugs in various stages of clinical development, including Phase II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations and the latest news and press releases.
Seborrhoeic Dermatitis Emerging Drugs
- Topisk roflumilastskum (ARQ-154): Arcutis Biotherapeutics
Topical roflumilast foam (ARQ-154) is a foam formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has demonstrated greater potency based on IC50 values (a non-clinical measure of a drug's potency) than any other described PDE4 inhibitor. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases the production of anti-inflammatory mediators and has been implicated in a wide variety of inflammatory diseases. Arcutis has initiated a phase 2 clinical trial to evaluate topical roflumilast foam for seborrheic dermatitis.
- Omiganan (CLS002): Cutanea Life Sciences
Chitosan (CLS002), an implantable bioresorbable gel based on chitin and chitosan for the treatment of soft tissue abnormalities of the skin. It is in phase II of clinical trials for the treatment of seborrhoeic dermatitis.
- DBI-002: DermBiont
Mechanism of action: Microbiome modulators. The drug is in preclinical studies for the treatment of Seborrhoeic Dermatitis.
- PAC-14028: Amorepacific
PAC-14028 was developed as a transient receptor potential vanilloid type 1 (TRPV1) antagonist. It is known that TRPV1 may be deeply associated with skin permeability barrier function, suggesting that modulation of TRPV1 may be beneficial for skin disorders with barrier damage. Amorepacific developed a topical cream formulation of PAC-14028. AC-14028 participated in phase II clinical trials to evaluate its safety and efficacy in seborrheic dermatitis
Seborrheic dermatitis: Therapeutic assessment
This segment of the report provides insight into the various seborrheic dermatitis drugs separately based on the following parameters that define the scope of the report such as:
Main players in Seborrhoeic Dermatitis
It's about. 5+ key companies developing therapies for seborrhoeic dermatitis. The companies that have their drug candidates for Seborrhoeic Dermatitis in the middle to advanced stage, ie. phase II, includes Arcutis Biotherapeutics and others.
The report covers about 5+ products in different phases of clinical development such as
- Products in the late phase (phase III)
- Mid-stage products (phase II and phase I/II)
- Early stage products (Phase I/II and Phase I) along with the details of
- Preclinical candidates and candidates in the Discovery phase
- Discontinued and inactive candidates
Administration road
Seborrhoeic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by route of administration. Products have been categorized under different ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscularly
- Parenteral
- Molecule type
Products have been categorized under different molecule types such as
- Small molecules
- Gene therapy
- Polymer
- Peptides
- Monoclonal antibodies
- product type
The drugs have been categorized under different product types such as Mono, Combination and Mono/Combination.
Seborrhoeic Dermatitis: Pipeline Development Activities
The report provides insight into various therapeutic candidates in Phase II, I, preclinical and discovery stages. It also analyzes seborrhoeic dermatitis therapeutic drugs key players involved in the development of key drugs.
Pipeline development activities
The report covers the detailed information on collaborations, acquisitions and mergers, licensing along with a thorough therapeutic evaluation of new drugs for seborrhoeic dermatitis.
Seborrhoeic Dermatitis Report Insights
- Seborrhoeic Dermatitis Pipeline Analyse
- Therapeutic assessment
- Unmet needs
- Impact of drugs
Seborrhoeic Dermatitis Report assessment
- Pipeline product profiles
- Therapeutic assessment
- Pipeline assessment
- Assessment of inactive substances
- Unmet needs
Key questions answered
Current treatment scenarios and new therapies:
- How many companies are developing drugs for Seborrhoeic Dermatitis?
- How many Seborrhoeic Dermatitis drugs are being developed by each company?
- How many new drugs are in mid- and late-stage development for the treatment of seborrheic dermatitis?
- What are the main collaborations (industry-industry, industry-academia), mergers and acquisitions, licensing activities related to the treatment of seborrheic dermatitis?
- What are the latest trends, drug types and new technologies developed to overcome the limitation of existing treatments?
- What are the clinical studies of seborrhoeic dermatitis and their status?
- What are the main names that have been given to the new drugs?
Key players
- Arcutis Biotherapeutics
- Cutanea Life Sciences
- DermBiont
- Astion Pharma A/S
- love pacific
Key products
- ARQ-154
- CLS002
- DBI-002
- ASF-1057
- PAC-14028
Table of Contents
Introduction
Executive Summary
Seborrhoeic Dermatitis: Overview
- Reasons
- Mechanism of action
- Signs and symptoms
- Diagnose
- Disease management
Therapeutic Pipelines
- Comparative analysis
Therapeutic assessment
- Assessment by product type
- Assessment by stage and product type
- Assessment by route of administration
- Assessment by stage and route of administration
- Assessment by molecule type
- Assessment by stage and molecule type
Seborrhoeic Dermatitis - Analytical Perspective
In-depth commercial assessment
- Seborrhoeic Dermatitis Company Collaborations, Licensing, Acquisitions - Deal Value Trends
Seborrhoeic Dermatitis Collaboration Agreements
- Business-business collaboration (Licensing / Partnering) Analysis
- Company-University collaboration (Licensing / Partnering) Analysis
Products in the late phase (phase III)
- Comparative analysis
ASF 1057: Astion Pharma A/S
- Product description
- Research and development
- Product development activities
Mid Stage Products (Phase II)
- Comparative analysis
ARQ-154: Arcutis Biotherapeutics
- Product description
- Research and development
- Product development activities
Preclinical products and products in the Discovery Stage
- Comparative analysis
DBI-002: Dermbiont
- Product description
- Research and development
- Product development activities
Inactive products
- Comparative analysis
Seborrhoeic Dermatitis Key Companies
Seborrhoeic dermatitis key products
Seborrhoeic dermatitis - unmet needs
Seborrhoeic Dermatitis - Market Drivers and Barriers
Seborrhoeic Dermatitis - Future Perspectives and Conclusion
Seborrhoeic Dermatitis Analyst Views
Seborrhoeic Dermatitis Key Companies
AppendixList of tables
Table 1 Total products for seborrheic dermatitis
Table 2 Late phase products
Table 3 Mid Stage Products
Table 4 Early products
Table 5 Preclinical products and products in the discovery phase
Table 6 Assessment by product type
Table 7 Assessment by stage and product type
Table 8 Assessment by route of administration
Table 9 Assessment by step and route of administration
Table 10 Assessment by molecule type
Table 11 Assessment by stage and molecule type
Table 12 Inactive productsList of figures
Figure 1 Total products for seborrheic dermatitis
Figure 2 Late-phase products
Figure 3 Mid Stage Products
Figure 4 Early products
Figure 5 Preclinical products and products in the discovery phase
Figure 6 Assessment by product type
Figure 7 Assessment by stage and product type
Figure 8 Assessment by route of administration
Figure 9 Assessment by stage and route of administration
Figure 10 Assessment by molecule type
Figure 11 Assessment by stage and molecule type
Figure 12 Inactive products
Mentioned companies
A selection of companies mentioned in this report include:
- Arcutis Biotherapeutics
- Cutanea Life Sciences
- DermBiont
- Astion Pharma A/S
- love pacific
FAQs
How big is the seborrheic dermatitis market? ›
Facts and Factors estimate that the global seborrheic dermatitis market was worth USD 2.2 billion in 2021 and will grow to USD 5 billion by 2030 at a CAGR of 11.1%.
Is there a treatment for seborrheic dermatitis in 2023? ›These results suggest roflumilast foam, 0.3%, has the potential to help address the unmet need for an effective, cosmetically tolerable, treatment for seborrheic dermatitis. Accepted for Publication: March 1, 2023.
Are there any new treatments for seborrheic dermatitis? ›The US Food and Drug Administration (FDA) has accepted Arcutis Biotherapeutics' New Drug Application (NDA) for roflumilast foam 0.3% for the treatment of seborrheic dermatitis in patients aged 9 years or older.
When will Roflumilast foam be available? ›The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2023. Roflumilast is a once-daily, topical phosphodiesterase type 4 (PDE4) inhibitor under development for the treatment of inflammatory dermatoses, focusing on the hair-bearing areas including the face, scalp, and trunk.
How many people in the US have seborrheic dermatitis? ›Seborrheic dermatitis is common: About 3 to 10 out of 100 people are affected. It's more common in men than in women.
What are the statistics on seborrheic dermatitis? ›The prevalence rate of seborrheic dermatitis is 3-5%, with a worldwide distribution.
Are they working on a cure for seborrheic dermatitis? ›Seborrhoeic dermatitis cannot be cured, because once an individual has become allergic to Malassezia on the skin, exposure to it will always cause a problem. The only way to keep it under control is to use anti-yeast treatments, which will suppress seborrhoeic dermatitis but not eradicate it.
What is the secret cure for seborrheic dermatitis? ›Tea tree oil. Tea tree oil has been studied for several skin conditions. Its antibacterial, antifungal, and anti-inflammatory benefits make it an ideal treatment for seborrheic dermatitis. Shampoo, conditioners, and other products that you can wash out may help relieve itching if they contain tea tree oil.
Will seborrheic dermatitis ever be cured? ›Treating seborrheic dermatitis in teens and adults: When teens and adults develop seborrheic dermatitis, the disease tends to come and go for years – and sometimes a lifetime. Treatment cannot cure seborrheic dermatitis, but it can: Lessen signs of the disease on your scalp and skin. Alleviate the itch and swelling.
Is seborrheic dermatitis a big deal? ›Seborrheic dermatitis causes no serious harm to the body, including the hair. It appears as red, dry, flaky, itchy skin on the scalp and other parts of the body and is common but not contagious. Its presence doesn't mean the skin is unclean or infected. Medications manage the symptoms.
What is the market size for dermatological therapeutics? ›
“As per the latest research analysis, the global dermatology drugs market size/share will be valued at roughly USD 17.28 Billion in 2022, and its revenue is projected to reach about USD 50.47 Billion By 2032.
What is the distribution of seborrheic dermatitis? ›Distribution follows the oily and hair-bearing areas of the head and the neck, such as the scalp, the forehead, the eyebrows, the lash line, the nasolabial folds, the beard, and the postauricular skin. An extension to submental skin can occur.
What is the market size of atopic dermatitis? ›| Report Coverage | Details |
|---|---|
| Market Size in 2021: | USD 15.20 Billion |
| Forecast Period: | 2021-2030 |
| Forecast Period 2021-2030 CAGR: | 10.5% |
| 2030 Value Projection: | USD 28.70 Billion |